RecruitingNCT04993859

Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Sponsor

University of Colorado, Denver

Enrollment

152 participants

Start Date

Jun 2, 2021

Study Type

OBSERVATIONAL

Conditions

Survivors of Childhood Cancer Bladder Dysfunction

Summary

The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.

Eligibility

Min Age: 5 YearsMax Age: 13 Years

Inclusion Criteria4

Children aged 5-13 years old
A history of cancer
Treatment with a chemotherapy regimen including VCR and/or DOX
Completion of chemotherapy at least one year prior to study enrollment and survey completion.

Exclusion Criteria8

Patients with a:
Primary pelvic tumor
Pelvic irradiation
Pre-existing bladder/bowel dysfunction
Spinal defects
Neurologic disorder
Neuro-oncologic tumor or brain metastasis
Cyclophosphamide or ifosfamide therapy

Interventions

DIAGNOSTIC_TESTNon-invasive Urodynamic Test (niUDS)

A noninvasive urodynamics is a simple test used to evaluate urinary flow.

DIAGNOSTIC_TESTUrinary proteomic screen

Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.

OTHERDysfunctional Voiding Symptom Score Survey (DVSS)

The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.